Cerebrospinal fluid (CSF) amyloid-β (Aβ) 42 and tau are biomarkers for Alzheimer's disease
(AD); however, the effects of other neurodegenerative processes on these biomarkers …

Neurodegenerative diseases represent a daunting challenge in clinical diagnosis and
management. Biomarkers that might aid in the diagnosis of these devastating and globally …

Biomarkers are one type of laboratory testing being developed in response to the
therapeutic imperative for diseases that cause cognitive impairment and dementia. The role …

In the 12 years since the publication of the first Consensus Paper of the WFSBP on
biomarkers of neurodegenerative dementias, enormous advancement has taken place in …

Background: Neuropathologically, Alzheimer's disease (AD) is characterized by
accumulation of a 42 amino acid peptide called amyloid-β (Aβ 42) in extracellular senile …

In view of the paucity of data on cerebrospinal fluid (CSF) biomarkers in Chinese patients,
we evaluated the validity of tau, phosphorylated tau 181 (p-tau-181), amyloid β 42 (Aβ42) …

Abstract Background Cerebrospinal fluid (CSF) Aβ1–42 levels and the Aβ1–42/Aβ1–40 ratio
are markers of amyloid pathology, but previous studies suggest that their levels might be …

The cerebrospinal fluid (CSF) biomarkers amyloid-β 42 (Aβ 42), total Tau, and phospho-181-
Tau represent important diagnostic tools to support the clinical diagnosis of Alzheimer's …

Objective: To investigate whether cerebrospinal fluid (CSF) biomarkers can predict cognitive
decline in healthy, elderly individuals as they have been shown to do in cognitively impaired …

Neurodegenerative diseases are a broad heterogeneous group affecting the nervous
system. They are characterized, from a pathophysiological perspective, by the selective …